{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:33:10Z","timestamp":1768350790005,"version":"3.49.0"},"reference-count":65,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016094","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:13:52Z","timestamp":1755774832000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunosuppressants for IgG4-related disease"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-8158","authenticated-orcid":false,"given":"Giovanni","family":"Cagnotto","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical Sciences Malm\u00f6; Lund University; Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecka Teresia","family":"B\u00e4cklund","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical Sciences Malm\u00f6; Lund University; Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical Sciences Lund; Lund University; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Bruschettini","sequence":"additional","affiliation":[{"name":"Cochrane Sweden, Department of Research and Education; Paediatrics, Department of Clinical Sciences Lund, Lund University, Sk\u00e5ne University Hospital, Lund, Sweden; Lund University, Sk\u00e5ne University Hospital; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"supported by Cochrane Sweden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD016094-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10165-011-0508-6","article-title":"A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details","volume":"22","author":"Umehara","year":"2012","journal-title":"Modern Rheumatology"},{"issue":"9976","key":"10.1002\/14651858.CD016094-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD016094-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD016094-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"Stone","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD016094-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nature Reviews Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD016094-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis & Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD016094-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Modern Pathology"},{"issue":"15","key":"10.1002\/14651858.CD016094-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1097\/MD.0000000000000680","article-title":"IgG4-related disease: dataset of 235 consecutive patients","volume":"94","author":"Inoue","year":"2015","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD016094-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/82_2016_36","article-title":"Diagnosis and treatment of IgG4-related disease","volume":"401","author":"Kamisawa","year":"2017","journal-title":"Current Topics in Microbiology & Immunology"},{"issue":"9","key":"10.1002\/14651858.CD016094-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/ajg.2009.325","article-title":"Evaluation and management of autoimmune pancreatitis: experience at a large US center","volume":"104","author":"Raina","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD016094-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016094-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"358371","DOI":"10.1155\/2012\/358371","article-title":"Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009","volume":"2012","author":"Uchida","year":"2012","journal-title":"International Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD016094-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/ard-2023-223950","article-title":"Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults","volume":"82","author":"Wallace","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD016094-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S2665-9913(24)00089-4","article-title":"Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of 328 patients fulfilling the American College of Rheumatology-European League Against Rheumatism classification criteria","volume":"6","author":"Jha","journal-title":"2024"},{"issue":"9","key":"10.1002\/14651858.CD016094-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD016094-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/key397","article-title":"Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD016094-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"i24","DOI":"10.1093\/rheumatology\/keaf008","article-title":"IgG4-related disease: lessons from the first 20 years","volume":"64","author":"Stone","year":"2025","journal-title":"Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD016094-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jaci.2014.03.034","article-title":"De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease","volume":"134","author":"Mattoo","year":"2014","journal-title":"Journal of Allergy & Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD016094-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/annrheumdis-2016-209139","article-title":"Lesional CD4+ IFN-\u03b3+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis","volume":"76","author":"Maehara","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD016094-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/gutjnl-2017-314548","article-title":"Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease","volume":"67","author":"Hubers","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD016094-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clim.2014.10.008","article-title":"Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease","volume":"156","author":"Furukawa","year":"2015","journal-title":"Clinical Immunology"},{"issue":"9","key":"10.1002\/14651858.CD016094-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39209","article-title":"Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease","volume":"67","author":"Akiyama","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD016094-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"e1913102","DOI":"10.1001\/jamanetworkopen.2019.13102","article-title":"Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis [Erratum in: JAMA Netw Open. 2020 Apr 1;3(4):e205507. doi: 10.1001\/jamanetworkopen.2020.5507]","volume":"2","author":"Bilal","year":"2019","journal-title":"JAMA Network Open"},{"issue":"19","key":"10.1002\/14651858.CD016094-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD016094-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD016094-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"e0183844","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PloS ONE [Electronic Resource]"},{"issue":"10","key":"10.1002\/14651858.CD016094-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s00535-003-1175-y","article-title":"A new clinicopathological entity of IgG4-related autoimmune disease","volume":"38","author":"Kamisawa","year":"2003","journal-title":"Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD016094-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3960\/jslrt.54.95","article-title":"IgG4-related disease: diagnostic methods and therapeutic strategies in Japan","volume":"54","author":"Masaki","year":"2014","journal-title":"Journal of Clinical & Experimental Hematopathology"},{"issue":"4","key":"10.1002\/14651858.CD016094-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/kez380","article-title":"Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis","volume":"59","author":"Omar","year":"2020","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD016094-BIB0030|cit30","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016094-BIB0031|cit31","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual 2023"},{"key":"10.1002\/14651858.CD016094-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016094-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD016094-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10165-011-0571-z","article-title":"Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011","volume":"22","author":"Umehara","year":"2012","journal-title":"Modern Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD016094-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Modern Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD016094-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","article-title":"International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology","volume":"40","author":"Shimosegawa","year":"2011","journal-title":"Pancreas"},{"issue":"7","key":"10.1002\/14651858.CD016094-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3899\/jrheum.091153","article-title":"IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights","volume":"37","author":"Masaki","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD016094-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10157-011-0521-2","article-title":"Proposal for diagnostic criteria for IgG4-related kidney disease","volume":"15","author":"Kawano","year":"2011","journal-title":"Clinical & Experimental Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD016094-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00534-012-0521-y","article-title":"Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012","volume":"19","author":"Ohara","year":"2012","journal-title":"Journal of Hepato-Biliary-Pancreatic Sciences"},{"issue":"1","key":"10.1002\/14651858.CD016094-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10384-014-0352-2","article-title":"Diagnostic criteria for IgG4-related ophthalmic disease [Erratum in: Jpn J Ophthalmol. 2015 May;59(3):201. doi: 10.1007\/s10384-015-0376-2]","volume":"59","author":"Goto","year":"2015","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD016094-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.resinv.2015.09.002","article-title":"Proposed diagnostic criteria for IgG4-related respiratory disease","volume":"54","author":"Matsui","year":"2016","journal-title":"Respiratory Investigation"},{"issue":"4","key":"10.1002\/14651858.CD016094-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3400\/avd.oa.19-00085","article-title":"Clinical and pathological characteristics of IgG4-related periaortitis\/periarteritis and retroperitoneal fibrosis diagnosed based on experts' diagnosis","volume":"12","author":"Mizushima","year":"2019","journal-title":"Annals of Vascular Diseases"},{"issue":"6","key":"10.1002\/14651858.CD016094-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"Vollenhoven","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD016094-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3899\/jrheum.090373","article-title":"Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9","volume":"36","author":"Merkel","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD016094-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD016094-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"259408","DOI":"10.1155\/2012\/259408","article-title":"Development of an IgG4-RD responder index","volume":"2012","author":"Carruthers","year":"2012","journal-title":"International Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD016094-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An international multispecialty validation study of the IgG4-related disease responder index","volume":"70","author":"Wallace","year":"2018","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD016094-BIB0048|cit48","unstructured":"Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims; availability. 2009 Available from https:\/\/www.federalregister.gov\/documents\/2009\/12\/09\/E9-29273\/guidance-for-industry-on-patient-reported-outcome-measures-use-in-medical-product-development-to"},{"issue":"6","key":"10.1002\/14651858.CD016094-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"10","key":"10.1002\/14651858.CD016094-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD016094-BIB0051|cit51","unstructured":"ICH harmonised tripartite guideline. Clinical safety data management: definitions and standard for expedited reporting E2A. Step 4 version International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1994"},{"key":"10.1002\/14651858.CD016094-BIB0052|cit52","unstructured":"Covidence Veritas Health Innovation 2025"},{"issue":"24","key":"10.1002\/14651858.CD016094-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24%3C2815::aid-sim110%3E3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016094-BIB0054|cit54","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD016094-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016094-BIB0056|cit56","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016094-BIB0057|cit57","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016094-BIB0058|cit58","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2025"},{"issue":"8","key":"10.1002\/14651858.CD016094-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"7","author":"Tierney","year":"2007","journal-title":"Trials [Electronic Resource]"},{"issue":"10","key":"10.1002\/14651858.CD016094-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3899\/jrheum.090193","article-title":"The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36","volume":"36","author":"Colangelo","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD016094-BIB0061|cit61","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016094-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016094-BIB0063|cit63","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016094-BIB0064|cit64","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD016094-BIB0065|cit65","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:13:55Z","timestamp":1755774835000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016094"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":65,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016094","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}